Search Results
Kidney Cancer
Robert J. Motzer, Neeraj Agarwal, Clair Beard, Graeme B. Bolger, Barry Boston, Michael A. Carducci, Toni K. Choueiri, Robert A. Figlin, Mayer Fishman, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Anne Kessinger, Timothy M. Kuzel, Paul H. Lange, Ellis G. Levine, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Bruce G. Redman, Cary N. Robertson, Lawrence H. Schwartz, Joel Sheinfeld, and Jue Wang
Kidney Cancer
Robert J. Motzer, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Michael A. Carducci, Sam S. Chang, Toni K. Choueiri, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, David Josephson, Timothy M. Kuzel, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Thomas W. Ratliff, Bruce G. Redman, Cary N. Robertson, Charles J. Ryan, Joel Sheinfeld, Philippe E. Spiess, Jue Wang, and Richard B. Wilder
malignancies, with a median age at diagnosis of 65 years. The rate of RCC has increased by 2% per year for the past 65 years. The reason for this increase is unknown. Approximately 90% of renal tumors are RCC, and 85% of these are clear cell tumors. 2 Other
Updates in the Systemic Therapy Options for Clear Cell and Non–Clear Cell Renal Cell Carcinoma
Presented by: Philippe E. Spiess, Peter A.S. Johnstone, and Eric Jonasch
At the NCCN 2023 Annual Conference, experts reviewed clinical data on established therapies for patients with metastatic renal cell carcinoma and discussed strategies to effectively manage both clear cell and non–clear cell tumor histologies in the setting of advanced stages. Depicted through 3 separate case studies, they strategized the selection of optimal first-line and subsequent-line therapies based on the individual case study and the tumor characteristics in each.
Kidney Cancer, Version 2.2014
Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Kanishka Sircar, Brad Somer, Jue Wang, Richard B. Wilder, Mary A. Dwyer, and Rashmi Kumar
RCC has increased by 1.7% per year for the past 10 years. 2 Approximately 90% of renal tumors are RCC, and 85% of these are clear cell tumors. 3 Other less common cell types include papillary, chromophobe, “translocation-type,” and Bellini
Biallelic TSC2 Mutations in a Patient With Chromophobe Renal Cell Carcinoma Showing Extraordinary Response to Temsirolimus
Pablo Maroto, Georgia Anguera, Juan Maria Roldan-Romero, Maria Apellániz-Ruiz, Ferran Algaba, Jacqueline Boonman, Mark Nellist, Cristina Montero-Conde, Alberto Cascón, Mercedes Robledo, and Cristina Rodríguez-Antona
patient with metastatic chRCC. The optimum targeted therapy for chRCC is still not well-defined. Most trials for metastatic RCC are performed with clear cell tumors and include a limited number of chRCC cases. 21 , 25 – 27 A recent randomized phase II
Racial and Ethnic Disparities in the Time to Ovarian Cancer Surgery in Patients at an Integrated Health Care Delivery System
Amrita Mukherjee, Devansu Tewari, Rombod Rahimian, Qiaoling Chen, Michael Batech, Patricia Wride, Sandra Sappington, and Chun R. Chao
, those with serous, endometrioid, and clear cell tumors had a lower likelihood of having received surgery at any given time post diagnostic imaging (HR, 0.68 [95% CI, 0.51–0.90], 0.68 [95% CI, 0.50–0.92], and 0.56 [95% CI, 0.40–0.79], respectively
Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Sam Bhayani, William P. Bro, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Mayer Fishman, Thomas H. Gallagher, John L. Gore, Steven L. Hancock, Michael R. Harrison, Won Kim, Christos Kyriakopoulos, Chad LaGrange, Elaine T. Lam, Clayton Lau, M. Dror Michaelson, Thomas Olencki, Phillip M. Pierorazio, Elizabeth R. Plimack, Bruce G. Redman, Brian Shuch, Brad Somer, Guru Sonpavde, Jeffrey Sosman, Mary Dwyer, and Rashmi Kumar
are RCC, and approximately 80% of these are clear cell tumors. 2 , 3 Other less common cell types include papillary, chromophobe, translocation, and Bellini duct (collecting duct) tumors. Medullary renal carcinoma is a variant of collecting duct renal
NCCN Task Force Report: mTOR Inhibition in Solid Tumors
Robert A. Figlin, Elizabeth Brown, Andrew J. Armstrong, Wallace Akerley, Al B. Benson III, Harold J. Burstein, David S. Ettinger, Phillip G. Febbo, Matthew G. Fury, Gary R. Hudes, Merrill S. Kies, Eunice L. Kwak, Robert J. Morgan Jr., Joanne Mortimer, Karen Reckamp, Alan P. Venook, Frank Worden, and Yun Yen
that of interferon in patients with clear cell and non-clear cell histology; the latter histology constituted 20% to 25% of renal cell carcinomas. The 75 patients with non-clear cell tumors is the largest such population in any randomized trial. In this